Ua hoʻolaha ʻo Isleworth Healthcare Acquisition Corp. a me Cytovia Holdings, Inc. i kēia lā ua komo lākou i loko o kahi ʻaelike hui ʻoihana. I ka pau ʻana o kēia hui ʻana, e kapa ʻia ʻo Isleworth iā Cytovia Therapeutics, Inc. (ʻo ka "hui hui") a me kāna mau mea maʻamau a me nā palapala hōʻoia e manaʻo ʻia e waiho ʻia ma ka NASDAQ ma lalo o nā hōʻailona ticker INKC a me INKCW, kēlā me kēia.

E hoʻomau ka hui hui i nā hana a Cytovia a e hoʻomau i ka nānā ʻana i ka hoʻomohala ʻana a me ka hana ʻana i nā pūlima NK hoʻohui a me NK engager antibody platforms.

E alakaʻi ʻia ka hui hui ʻia e Dr. Daniel Teper, ka Co-Founder, Chairman, a me Luna Nui o Cytovia.

"Mahalo nui mākou i ke kākoʻo ikaika mai nā mea hoʻopukapuka hou a i kēia manawa a me ka hui o nā ʻoihana loea ma Isleworth. Manaʻo mākou i kēia kālepa e hoʻokō i ka manaʻo o Cytovia e holomua i nā lāʻau lapaʻau NK i kahi lāʻau no ka maʻi kanesa” wahi a Kauka Teper. "Ke paipai ʻia nei mākou e kā mākou ʻikepili preclinical i hōʻike ʻia ma AACR, e kākoʻo ana i ka hoʻomohala ʻana i kā mākou iPSC-derived NK cell (iNK) a me Flex-NK ™ cell engagers no ka mālama ʻana i ka Hepatocellular Carcinoma."

Ua ʻōlelo ʻo Bob Whitehead, Luna Nui o Isleworth: "Ua loiloi ʻo Isleworth i nā ʻoihana ʻepekema ola a mahalo nui ʻia e nā talena a me nā ʻenehana i hōʻuluʻulu ʻia e Cytovia. Ke manaʻoʻiʻo nei mākou ʻo Cytovia kekahi o nā ʻoihana hoʻomaʻamaʻa cell hou loa e pili ana i ka hoʻomohala ʻana i nā lāʻau lapaʻau hou. ʻO nā lāʻau lapaʻau ma ka oncology ua lawe mai i ka manaolana i nā miliona. Hiki i nā ala o Cytovia ke hana i nā ala like i ʻoi aku ka maʻalahi o ka 'off-the-shelf' a me ke kumukūʻai.

ʻO Cytovia's Therapeutic Approach

Manaʻo ʻo Cytovia e hoʻolalelale i ka loaʻa ʻana o ka mea maʻi i ka hoʻololi ʻana i nā cell therapies a me nā immunotherapies, e kamaʻilio ana i kekahi o nā mea paʻakikī paʻakikī loa e pono ai i ka oncology.

Kūleʻa ka hui i ka hoʻohana ʻana i ka ʻōnaehana immune innate ma o ka hoʻomohala ʻana i nā pūnaewele NK-cell a me NK-engager antibody hoʻohui a hoʻopilikia. ʻO ke ʻano kikoʻī, ke kūkulu nei ʻo Cytovia i ʻekolu ʻano o nā pūnaewele iNK: nā pūnaewele iNK i hoʻoponopono ʻole ʻia, nā pūnaewele iNK i hoʻoponopono ʻia ʻo TALEN® me ka hoʻomaikaʻi ʻana i ka hana a me ka hoʻomau, a me TALEN® gene-edited iNK cell with chimeric antigen receptors (CAR-iNKs) no ka hoʻomaikaʻi ʻana i ke kiko kikoʻī. hoʻopaʻa ʻana. ʻO ka ʻenehana pōhaku kihi koʻikoʻi ʻelua, ʻo ia ka quadrivalent multispecific antibody platform i hoʻolālā ʻia e hoʻopili i nā pūnaewele NK ma o ka huli ʻana i ka NKp46 activating receptor me ka hoʻohana ʻana i ka ʻenehana Flex-NK™.

Ke hoʻohana ʻia nei kēia mau ʻenehana ʻenehana ʻelua no ka hoʻomohala ʻana i nā lāʻau lapaʻau no nā poʻe maʻi me ka Hepatocellular Carcinoma (HCC) a me nā ʻōpū paʻa. Manaʻo ʻia ka hoʻomaka ʻana o nā noiʻi maʻi ma ka hopena o 2022.

ʻO ke keʻena nui ma Aventura, FL, Cytovia e hana ana i nā laboratories R&D ma Natick, MA a me kahi hale hana cGMP cell ma Puerto Rico a loaʻa iā ia nā hui ʻepekema me Cellectis, CytoImmune Therapeutics, ke Kulanui Hebera o Ierusalema, INSERM, ka New York Stem Cell Foundation, ka National Cancer Institute, a me ke Kulanui o Kaleponi San Francisco (UCSF). Ua hoʻokumu hou ʻo Cytovia Therapeutics iā CytoLynx Therapeutics, kahi hui hoʻolālā e pili ana i ka noiʻi a me ka hoʻomohala ʻana, ka hana ʻana, a me nā hana kālepa ma Greater China a ma waho.

Cytovia Pipeline

ʻO Cytovia ka hui immune-oncology mua me ka hiki ke hoʻohui i ka iPSC-derived NK Cell a me Flex-NK ™ cell engager antibody platforms e hoʻomohala i ka hanauna hou o immunotherapies no nā maʻi hematological a paʻa.

Aia i loko o ka waihona o Cytovia nā pahu hopu a me nā hōʻailona me kahi ʻaoʻao pilikia kaulike.

ʻO GPC3 kahi pahuhopu moʻolelo hoʻohiki no nā maʻi koko paʻa, ʻoi aku ka maʻi hepatocellular carcinoma, kahi i koʻikoʻi ai ka pono olakino. Manaʻo ka papahana alakaʻi a Cytovia e hoʻomohala i nā lāʻau lapaʻau HCC papa mua e kuhikuhi ana iā GPC3. E loiloi ʻia nā moho huahana ʻehā ma ke ʻano he monotherapies a ma ke ʻano he lāʻau lapaʻau hui. ʻO CYT-303, Cytovia's GPC3 Flex-NK ™ engager, he ʻano antibody tri-specific e hoʻopaʻa ana i nā pūnaʻi tumo HCC ma o GPC3 a i nā pūnaewele NK ma o NKp46 a me CD16a. No nā poʻe maʻi me ka helu impaired a i ʻole ka hana o nā pūnaewele NK, e loiloi ʻo Cytovia i ka hoʻohui ʻana o nā cell iNK, CYT-100, e wehe paha i ka mana piha o kēia hoʻolālā lapaʻau. Ke hoʻomohala nei ʻo Cytovia i ka CYT-150, nā pūnaewele iNK i hoʻoponopono ʻia, e hoʻomaikaʻi i ka infiltration tumor a me ka hoʻomau ʻana o ke kelepona, hiki ke hui pū ʻia me CYT-303. Eia kekahi, ua hoʻolālā ʻia ʻo CYT-503, kahi GPC3-targeting CAR-iNK cell therapeutic, e hoʻomaikaʻi i ka kikoʻī no ka huli ʻana i ka tumor. Manaʻo ʻo Cytovia e waiho i nā IND no CYT-303 a me CYT-100, a ukali ʻia e nā IND no CYT-150 a me CYT-503.

ʻO CD38 kahi pahu lapaʻau i hoʻokumu maikaʻi ʻia no Multiple Myeloma. Ke hoʻomohala nei ʻo Cytovia i ka CYT-338 a me CYT-538, ʻo ia hoʻi, nā CD38-targeting Flex-NK™ cell engagers a me CAR-iNK cell no ka mālama ʻana o Multiple Myeloma i nā poʻe maʻi i hāʻule i ka CD38 antibody therapies a me nā mea hana e kuhikuhi ana i ka maturation B-cell. antigen (BCMA).

Ke hoʻomohala nei ʻo Cytovia i kahi moho EGFR CAR iNK intracranial e hoʻopaʻa i ka wtEGFR a me EGFR vIII no ka hoʻoponopono ʻana i kahi pono olakino koʻikoʻi i ka mālama ʻana i ka Glioblastoma multiforme hiki ʻole ke hoʻoponopono ʻia i kēia manawa.

Ua hoʻokumu ʻo Cytovia i ka hui pū ʻana me nā ʻoihana hoʻonaʻauao a me nā hoa hana ʻoihana me Cellectis no TALEN® hoʻoponopono gene. ʻO ka TALEN® gene-editing he ʻenehana i paionia a hoʻomalu ʻia e Cellectis, kahi hui biotechnology o ke kahua lapaʻau e hoʻohana ana i kāna kahua hoʻoponopono gene e hoʻomohala i nā cellola ola a me nā lāʻau lapaʻau gene. ʻO ka TALEN® gene-edited patents i mālama ʻia e Cellectis ma ke kahua o iNK a me CAR-iNK ua laikini ʻia mai Cellectis e Cytovia a paʻa ʻo Cytovia i ka hoʻomohala honua a me nā kuleana kalepa i kēia mau patent.

Nā Milestone i hoʻolālā ʻia a me ka hoʻohana ʻana i nā loaʻa kālā

ʻO nā kālā i loaʻa mai nā hoʻokomo pilikino (ka "PIPE"), nā kālā i loko o ka waihona hilinaʻi o Isleworth (net of redemptions), a me nā loaʻa mai nā kālā kālā ʻē aʻe, ma ka huina hui a hiki i hoʻokahi haneli miliona mau kālā, e hāʻawi iā Cytovia me ke kapikala a hiki i 2 makahiki e hoʻomohala hou i kāna mau ʻenehana iNK i hoʻoponopono ʻia a me Flex-NK™. Hoʻolālā ʻo Cytovia e kālele i nā milestone he nui, me:

• Waiho i nā IND mua ʻelua no Flex-NK™ CYT-303 a me iNK CYT-100

• Hoʻomaka i nā hoʻokolohua lapaʻau Phase I / II e loiloi i ka CYT-303 a me CYT-100, hoʻokahi a hui pū ʻia, no ka mālama ʻana i ka HCC

• Loaʻa a hōʻike i ka ʻikepili lapaʻau mua no CYT-303 a me CYT-100 ma HCC

• Waiho i nā IND no CYT-150 a me CYT-503 a hoʻomaka i nā hoʻokolohua lapaʻau Phase I/II

• Ke hoʻomau nei i ka hoʻomaikaʻi ʻana i nā ʻenehana iNK & Flex-NK™ a holomua i ka pipeline me nā moho lapaʻau he nui.